Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche In Stand-by Mode To Supply Tamifl& To Indian Government; Others Queue Up Too

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - As the Indian government grapples with the threat of influenza H1N1 through countrywide moves to stockpile drugs, protective masks and diagnostic kits, Roche India has said it has been approached for supplies of Tamiflu (oseltamivir) by the Indian health ministry but there are no clear orders issued yet to commence supply of the drugs

You may also be interested in...



As H1N1 Virus Spreads Fast In India, Government Ups Its Offensive

MUMBAI - India's health ministry has gone into hyperactive mode to combat the spread of the A/H1N1 influenza virus. The disease has claimed 14 lives over the last five days, while close to 1,000 more people tested positive and were treated in government-run hospitals

As H1N1 Virus Spreads Fast In India, Government Ups Its Offensive

MUMBAI - India's health ministry has gone into hyperactive mode to combat the spread of the A/H1N1 influenza virus. The disease has claimed 14 lives over the last five days, while close to 1,000 more people tested positive and were treated in government-run hospitals

Roche Ally Hetero Drugs Beat Ranbaxy, Cipla To Win Oseltamivir Supply Contract From Indian Government

MUMBAI - Hetero Drugs has edged past bigger Indian rivals Ranbaxy and Cipla to bag the government tender floated for supplies of oseltamivir. Hetero received orders to supply nine million capsules of generic versions of Roche's anti-viral brand Tamiflu. The entire contract is believed to be worth $6 to $8 million

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071797

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel